A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, phase 1 study of BBI608 and BBI503 administered orally
in combination to patients with advanced solid tumors. The primary goal is to determine the
safety, tolerability, and recommended phase II dose (RP2D) of the combination regimen.
Phase:
Phase 1
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc